Eli Lilly & Co. has seen a significant increase in its stock price due to two major updates that have attracted the attention of investors.

The positive sentiment surrounding the stock is partly due to the company's Zepbound injection pen, which was showcased in Brooklyn, New York.

Financial commentator Jim Cramer has expressed strong support for Eli Lilly, aligning himself with bullish investors who are discussing the implications of the recent news.

The market's reaction indicates a growing confidence in the company's future prospects as stakeholders consider the potential impact of these developments on its performance.